Monoclonal antibodies in the treatment of lymphoid leukemia.
MoAb-based therapies are evolving into the first broad-spectrum class of targeted anti-leukemic therapy. Developments in many areas, including computer modeling of receptors and ligands, and increasing sophistication in recombinant technologies may result in a rapid increase in the number and complexity of MoAb available. We can anticipate an increase in the number of safer conjugates being delivered to leukemia cells. Further understanding of the in-vitro mechanisms involved in tumor cell killing by MoAb will be important in maximizing the efficacy of this approach.
O'Brien
Susan
S
Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA. sobrien@mdanderson.org
Giles
Francis J
FJ
D000074323:Alemtuzumab; D000906:Antibodies; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004768:Enterotoxins; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage / Q000627:therapeutic use*; D007945:Leukemia, Lymphoid / Q000276:immunology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab
D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D004768:Enterotoxins; D000922:Immunotoxins; C431326:RFB4(dsFv)-PE38 recombinant immunotoxin; D000074323:Alemtuzumab; D000069283:Rituximab; C448699:apolizumab